Pasar al contenido principal

DESARROLLO DE UN NUEVO BIOMARCADOR Y SU KIT PARA PREDECIR LA RESISTENCIA A ANTIANGIOGENICOS EN CANCER - ANGIOBIOMARK

DTS17/00194

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Desarrollo Tecnológico en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION IDIBELL
Centro realización INSTITUTO DE INVESTIGACION BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Prediction of the response to antiangiogenic sunitinib therapy by non-invasive hybrid diffuse optics in renal cell carcinoma

  • Mireles, Miguel
  • Jimenez-Valerio, Gabriela
  • Morales Dalmau, Jordi
  • Johansson, Johannes D.
  • Martínez-Lozano, Mar
  • Vidal-Rosas, Ernesto E.
  • Navarro-Perez, Valentí
  • Busch, David R.
  • Casanovas, Oriol
  • Durduran, Turgut
  • Vilches, Clara
In this work, broadband diffuse reflectance spectroscopy (DRS) and diffuse correlation spectroscopy (DCS) were used to quantify deep tissue hemodynamics in a patient-derived orthotopic xenograft mouse model of clear cell renal cancer undergoing antiangiogenic treatment. A cohort of twenty-two mice were treated with sunitinib and compared to thirteen control untreated mice, and monitored by DRS/DCS. A reduction in total hemoglobin concentration (THC, p = 0.03), oxygen saturation (SO2, p = 0.03) and blood flow index (BFI, p = 0.02) was observed over the treatment course. Early changes in tumor microvascular blood flow and total hemoglobin concentration were correlated with the final microvessel density (p = 0.014) and tumor weight (p = 0.024), respectively. Higher pre-treatment tumor microvascular blood flow was observed in non-responder mice with respect to responder mice, which was statistically predictive of the tumor intrinsic resistance (p = 0.01). This hybrid diffuse optical technique provides a method for predicting tumor intrinsic resistance to antiangiogenic therapy and could be used as predictive biomarker of response to antiangiogenic therapies in pre-clinical models., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Kidney cancer PDOXs reveal patient-specific pro-malignant effects of antiangiogenics and its molecular traits

  • Moserle, Lidia
  • Pons, Roser
  • Martínez-Lozano, Mar
  • Jiménez-Valerio, Gabriela A
  • Vidal, August
  • Suárez Rodríguez, Cristina
  • Trilla Herrera, Enric
  • Jiménez Flores, José Antonio
  • Torres Ramirez, Inés de
  • Carles Galceran, Joan
Antiangiogènica; Resistència al càncer; Inducció de metàstasi, Antiangiogénico; Resistencia al cáncer; Inducción de metástasis, Antiangiogenic; Cancer resistance; Induction of metastasis, An open debate in antiangiogenic therapies is about their consequence on tumor invasiveness and metastasis, which is undoubtedly relevant for patients currently treated with antiangiogenics, such as renal cell carcinoma patients. To address, this we developed an extensive series of 27 patient biopsy-derived orthotopic xenograft models (Ren-PDOX) that represent inter-patient heterogeneity. In specific tumors, antiangiogenics produced increased invasiveness and metastatic dissemination, while in others aggressiveness remained unchanged. Mechanistically, species-discriminative RNA sequencing identified a tumor cell-specific differential expression profile associated with tumor progression and aggressivity in TCGA RCC patients. Gene filtering using an invasion-annotated patient series pinpointed two candidate genes, of which ALDH1A3 differentiated the pro-invasive subtype of Ren-PDOXs. Validation in an independent series of 15 antiangiogenic-treated patients confirmed that pre-treatment ALDH1A3 can significantly discriminate patients with pro-aggressive response upon treatment. Overall, results confirm that effects of antiangiogenic drugs on tumor invasion and metastasis are heterogeneous and may profoundly affect the natural progression of tumors and promote malignancy. Furthermore, we identify a specific molecular biomarker that could be used to select patients that better benefit from treatment., This work was supported by research grants from ERC (ERC-StG-281830) EU-FP7, Ministerio de Ciencia, Innovación y Universidades, through the Retos Investigación grant, Refs: SAF2016-79347-R and PID2019-107557RB-I00/AEI/10.13039/501100011033, ISCIII Spain (AES, DTS17/00194), AGAUR-Generalitat de Catalunya (2017SGR771), Marató de TV3 (201910-30-31-32) and Italian Association for Cancer Research (AIRC) IG#14032, DOR - University of Padova, IOV 5x1000 fund. We thank CERCA Programme / Generalitat de Catalunya for institutional support.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Kidney cancer PDOXs reveal patient-specific pro-malignant effects of antiangiogenics and its molecular traits

  • Moserle, Lidia
  • Pons, Roser
  • Martínez-Lozano, Mar
  • Jiménez-Valerio, Gabriela A
  • Vidal, August
  • Suárez Rodríguez, Cristina
  • Trilla Herrera, Enric
  • Jiménez Flores, José Antonio
  • Torres Ramirez, Inés de
  • Carles Galceran, Joan
Antiangiogènica; Resistència al càncer; Inducció de metàstasi, Antiangiogénico; Resistencia al cáncer; Inducción de metástasis, Antiangiogenic; Cancer resistance; Induction of metastasis, An open debate in antiangiogenic therapies is about their consequence on tumor invasiveness and metastasis, which is undoubtedly relevant for patients currently treated with antiangiogenics, such as renal cell carcinoma patients. To address, this we developed an extensive series of 27 patient biopsy-derived orthotopic xenograft models (Ren-PDOX) that represent inter-patient heterogeneity. In specific tumors, antiangiogenics produced increased invasiveness and metastatic dissemination, while in others aggressiveness remained unchanged. Mechanistically, species-discriminative RNA sequencing identified a tumor cell-specific differential expression profile associated with tumor progression and aggressivity in TCGA RCC patients. Gene filtering using an invasion-annotated patient series pinpointed two candidate genes, of which ALDH1A3 differentiated the pro-invasive subtype of Ren-PDOXs. Validation in an independent series of 15 antiangiogenic-treated patients confirmed that pre-treatment ALDH1A3 can significantly discriminate patients with pro-aggressive response upon treatment. Overall, results confirm that effects of antiangiogenic drugs on tumor invasion and metastasis are heterogeneous and may profoundly affect the natural progression of tumors and promote malignancy. Furthermore, we identify a specific molecular biomarker that could be used to select patients that better benefit from treatment., This work was supported by research grants from ERC (ERC-StG-281830) EU-FP7, Ministerio de Ciencia, Innovación y Universidades, through the Retos Investigación grant, Refs: SAF2016-79347-R and PID2019-107557RB-I00/AEI/10.13039/501100011033, ISCIII Spain (AES, DTS17/00194), AGAUR-Generalitat de Catalunya (2017SGR771), Marató de TV3 (201910-30-31-32) and Italian Association for Cancer Research (AIRC) IG#14032, DOR - University of Padova, IOV 5x1000 fund. We thank CERCA Programme / Generalitat de Catalunya for institutional support.